API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
HALDOL® (haloperidol decanoate) is a first-generation ‘typical’ antipsychotic for the treatment of schizophrenia and some other psychiatric conditions such as schizoaffective disorder and moderate to severe manic episodes associated with bipolar I disorder.
Lead Product(s): Haloperidol Decanoate
Therapeutic Area: Psychiatry/Psychology Product Name: Haldol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Essential Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 07, 2022